Roche agreed to buy PathAI in a deal valued at $750 million upfront to expand AI-powered digital pathology capabilities. PathAI’s technology supports pathology laboratories and biopharma partners with computational workflows intended to improve diagnostic and research efficiency. The acquisition adds another AI tooling asset to Roche’s diagnostics and R&D strategy, at a time when pathology automation and model-based decision support are becoming core components of drug development and companion diagnostics. Deal timing and integration details were not provided in the excerpt, but the upfront price highlights the competitive value investors are placing on digital pathology platforms.